Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Fanning

Foot and Ankle Surgery Wichita, KS Medical Doctor

NPI 1306813571 CMS profile 13615

9828 E Shannon Woods Cir # 100, Wichita, KS 67226

Open in the dashboard

General payments

$6,138

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Fanning of Wichita, KS is reported in the CMS Open Payments database as having received $6,138 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $847 9
2024 General $89 2
2023 General $2,076 23
2022 General $100 1
2021 General $1,735 12
2020 General $550 16
2019 General $741 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Fanning
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to John Fanning were reported at $847. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year John Fanning Foot and Ankle Surgery median Middle half National median
2019 $741 $1,327 $279–$5,421 $163
2020 $550 $795 $121–$3,473 $114
2021 $1,735 $1,289 $201–$4,963 $132
2022 $100 $1,539 $270–$6,067 $149
2023 $2,076 $1,117 $257–$5,264 $160
2024 $89 $1,064 $235–$4,944 $164
2025 $847 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Titan Surgical Group, LLC $1,727 10 payments
  2. Arthrex, Inc. $1,697 21 payments
  3. Treace Medical Concepts, Inc. $1,451 12 payments
  4. Stryker Corporation $573 9 payments
  5. Bard Peripheral Vascular, Inc. $236 15 payments
  6. Wright Medical Technology, Inc. $216 2 payments
  7. Acumed LLC $150 2 payments
  8. Lima USA, Inc. $25 1 payment
  9. Smith+Nephew, Inc. $21 1 payment
  10. Arthrosurface Incorporated $16 1 payment
  11. Other $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,604 10 payments
  2. Food and Beverage $2,533 66 payments
Products named General payments · program years 2019–2025
  1. Lapiplasty System $1,047 10 payments
  2. 7 X 23MM CITRELOCK IMPLANT $378 6 payments
  3. LAPIPLASTY SYSTEM 1 $251 1 payment
  4. DART-FIRE $195 2 payments
  5. TMC NANOPLASTY SYSTEM $153 1 payment
  6. ACUMED $128 1 payment
  7. InFrame Implant $128 1 payment
  8. BIO4 $127 3 payments
  9. ORTHOLOC $122 1 payment
  10. CITREFIX $117 1 payment
  11. Other $1,217 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

137

Median for Orthopedic Surgery: 203

Drug cost

$1,205

Median for Orthopedic Surgery: $1,433

Branded share of claims

67.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 41 $622
Ondansetron Odt Ondansetron Brand 36 $179
Doxycycline Hyclate Generic 12 $152
Cyclobenzaprine Hcl Generic 33 $144
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$69,689

Of which drugs: $147

Medicare patients

193

Average age 72

Services billed

2,274

134 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 61%
Depression 29%
Ischemic heart disease 24%
Diabetes 19%
Atrial fibrillation 16%
Chronic kidney disease 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 1,060 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record